197 related articles for article (PubMed ID: 18946890)
1. Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial.
Califf RM; Boolell M; Haffner SM; Bethel M; McMurray J; Duggal A; Holman RR;
Am Heart J; 2008 Oct; 156(4):623-32. PubMed ID: 18946890
[TBL] [Abstract][Full Text] [Related]
2. Baseline characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial population: comparison with other diabetes prevention trials.
Krum H; McMurray JJ; Horton E; Gerlock T; Holzhauer B; Zuurman L; Haffner SM; Bethel MA; Holman RR; Califf RM
Cardiovasc Ther; 2010 Apr; 28(2):124-32. PubMed ID: 20184589
[TBL] [Abstract][Full Text] [Related]
3. Effect of valsartan on the incidence of diabetes and cardiovascular events.
; McMurray JJ; Holman RR; Haffner SM; Bethel MA; Holzhauer B; Hua TA; Belenkov Y; Boolell M; Buse JB; Buckley BM; Chacra AR; Chiang FT; Charbonnel B; Chow CC; Davies MJ; Deedwania P; Diem P; Einhorn D; Fonseca V; Fulcher GR; Gaciong Z; Gaztambide S; Giles T; Horton E; Ilkova H; Jenssen T; Kahn SE; Krum H; Laakso M; Leiter LA; Levitt NS; Mareev V; Martinez F; Masson C; Mazzone T; Meaney E; Nesto R; Pan C; Prager R; Raptis SA; Rutten GE; Sandstroem H; Schaper F; Scheen A; Schmitz O; Sinay I; Soska V; Stender S; Tamás G; Tognoni G; Tuomilehto J; Villamil AS; Vozár J; Califf RM
N Engl J Med; 2010 Apr; 362(16):1477-90. PubMed ID: 20228403
[TBL] [Abstract][Full Text] [Related]
4. Effect of nateglinide on the incidence of diabetes and cardiovascular events.
; Holman RR; Haffner SM; McMurray JJ; Bethel MA; Holzhauer B; Hua TA; Belenkov Y; Boolell M; Buse JB; Buckley BM; Chacra AR; Chiang FT; Charbonnel B; Chow CC; Davies MJ; Deedwania P; Diem P; Einhorn D; Fonseca V; Fulcher GR; Gaciong Z; Gaztambide S; Giles T; Horton E; Ilkova H; Jenssen T; Kahn SE; Krum H; Laakso M; Leiter LA; Levitt NS; Mareev V; Martinez F; Masson C; Mazzone T; Meaney E; Nesto R; Pan C; Prager R; Raptis SA; Rutten GE; Sandstroem H; Schaper F; Scheen A; Schmitz O; Sinay I; Soska V; Stender S; Tamás G; Tognoni G; Tuomilehto J; Villamil AS; Vozár J; Califf RM
N Engl J Med; 2010 Apr; 362(16):1463-76. PubMed ID: 20228402
[TBL] [Abstract][Full Text] [Related]
5. [NAVIGATOR: A trial of prevention of cardiovascular complications and type 2 diabetes with valsartan and/or nateglinide].
Scheen AJ
Rev Med Liege; 2010 Apr; 65(4):217-23. PubMed ID: 20499825
[TBL] [Abstract][Full Text] [Related]
6. International Variation in Outcomes Among People with Cardiovascular Disease or Cardiovascular Risk Factors and Impaired Glucose Tolerance: Insights from the NAVIGATOR Trial.
Harumi Higuchi Dos Santos M; Sharma A; Sun JL; Pieper K; McMurray JJ; Holman RR; Lopes RD
J Am Heart Assoc; 2017 Jan; 6(1):. PubMed ID: 28087508
[TBL] [Abstract][Full Text] [Related]
7. Incidence of atrial fibrillation in a population with impaired glucose tolerance: the contribution of glucose metabolism and other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.
Latini R; Staszewsky L; Sun JL; Bethel MA; Disertori M; Haffner SM; Holman RR; Chang F; Giles TD; Maggioni AP; Rutten GE; Standl E; Thomas L; Tognoni G; Califf RM; McMurray JJ
Am Heart J; 2013 Nov; 166(5):935-40.e1. PubMed ID: 24176451
[TBL] [Abstract][Full Text] [Related]
8. Predictors of incident heart failure hospitalizations among patients with impaired glucose tolerance: insight from the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research study.
Wong YW; Thomas L; Sun JL; McMurray JJ; Krum H; Hernandez AF; Rutten GE; Leiter LA; Standl E; Haffner SM; Mazzone T; Martinez FA; Tognoni G; Giles T; Califf RM
Circ Heart Fail; 2013 Mar; 6(2):203-10. PubMed ID: 23388113
[TBL] [Abstract][Full Text] [Related]
9. Predictors of stroke in patients with impaired glucose tolerance: results from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.
Preiss D; Giles TD; Thomas LE; Sun JL; Haffner SM; Holman RR; Standl E; Mazzone T; Rutten GE; Tognoni G; Chiang FT; McMurray JJ; Califf RM
Stroke; 2013 Sep; 44(9):2590-3. PubMed ID: 23899915
[TBL] [Abstract][Full Text] [Related]
10. Effects of changes in potassium with valsartan use on diabetes risk: Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial.
Chatterjee R; Thomas L; Svetkey L; Brancati FL; Califf RM; Edelman D
Am J Hypertens; 2013 Jun; 26(6):723-6. PubMed ID: 23417031
[TBL] [Abstract][Full Text] [Related]
11. Venous thromboembolism and cardiovascular risk: results from the NAVIGATOR trial.
Katz M; Califf RM; Sun JL; McMurray JJ; Thomas L; Lopes RD
Am J Med; 2015 Mar; 128(3):297-302. PubMed ID: 25447626
[TBL] [Abstract][Full Text] [Related]
12. Role of diuretics, β blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study.
Shen L; Shah BR; Reyes EM; Thomas L; Wojdyla D; Diem P; Leiter LA; Charbonnel B; Mareev V; Horton ES; Haffner SM; Soska V; Holman R; Bethel MA; Schaper F; Sun JL; McMurray JJ; Califf RM; Krum H
BMJ; 2013 Dec; 347():f6745. PubMed ID: 24322398
[TBL] [Abstract][Full Text] [Related]
13. Navigating the choices for diabetes prevention.
Nathan DM
N Engl J Med; 2010 Apr; 362(16):1533-5. PubMed ID: 20228400
[No Abstract] [Full Text] [Related]
14. Determining the most appropriate components for a composite clinical trial outcome.
Bethel MA; Holman R; Haffner SM; Califf RM; Huntsman-Labed A; Hua TA; McMurray J
Am Heart J; 2008 Oct; 156(4):633-40. PubMed ID: 18926145
[TBL] [Abstract][Full Text] [Related]
15. Impact of baseline physical activity and diet behavior on metabolic syndrome in a pharmaceutical trial: results from NAVIGATOR.
Huffman KM; Sun JL; Thomas L; Bales CW; Califf RM; Yates T; Davies MJ; Holman RR; McMurray JJ; Bethel MA; Tuomilehto J; Haffner SM; Kraus WE
Metabolism; 2014 Apr; 63(4):554-61. PubMed ID: 24559843
[TBL] [Abstract][Full Text] [Related]
16. Prospective relationships between body weight and physical activity: an observational analysis from the NAVIGATOR study.
Preiss D; Thomas LE; Wojdyla DM; Haffner SM; Gill JM; Yates T; Davies MJ; Holman RR; McMurray JJ; Califf RM; Kraus WE;
BMJ Open; 2015 Aug; 5(8):e007901. PubMed ID: 26275900
[TBL] [Abstract][Full Text] [Related]
17. Valsartan improves {beta}-cell function and insulin sensitivity in subjects with impaired glucose metabolism: a randomized controlled trial.
van der Zijl NJ; Moors CC; Goossens GH; Hermans MM; Blaak EE; Diamant M
Diabetes Care; 2011 Apr; 34(4):845-51. PubMed ID: 21330640
[TBL] [Abstract][Full Text] [Related]
18. [Effects of nateglinide in impaired glucose tolerance subjects].
Hirose T
Nihon Rinsho; 2005 Feb; 63 Suppl 2():438-43. PubMed ID: 15779419
[No Abstract] [Full Text] [Related]
19. Nateglinide improves early insulin secretion and controls postprandial glucose excursions in a prediabetic population.
Saloranta C; Guitard C; Pecher E; De Pablos-Velasco P; Lahti K; Brunel P; Groop L
Diabetes Care; 2002 Dec; 25(12):2141-6. PubMed ID: 12453951
[TBL] [Abstract][Full Text] [Related]
20. Role of renin-angiotensin system blockade in patients with diabetes mellitus.
Braga MF; Leiter LA
Am J Cardiol; 2009 Sep; 104(6):835-9. PubMed ID: 19733720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
